Kyung Nam Pharm Co.,Ltd. (KOSDAQ:053950)
South Korea
· Delayed Price · Currency is KRW 642.00
-7.00 (-1.08%)
At close: Mar 21, 2025, 3:30 PM KST
Kyung Nam Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 60,792 | 59,303 | 59,000 | 64,623 | 70,933 | Upgrade
|
| Other Revenue | -0 | - | - | - | -0 | Upgrade
|
| Revenue | 60,792 | 59,303 | 59,000 | 64,623 | 70,933 | Upgrade
|
| Revenue Growth (YoY) | 2.51% | 0.51% | -8.70% | -8.89% | 58.31% | Upgrade
|
| Cost of Revenue | 43,567 | 40,006 | 42,632 | 43,614 | 42,258 | Upgrade
|
| Gross Profit | 17,225 | 19,298 | 16,368 | 21,010 | 28,674 | Upgrade
|
| Selling, General & Admin | 17,321 | 21,709 | 19,039 | 27,773 | 25,077 | Upgrade
|
| Other Operating Expenses | 276.43 | 222.06 | 194.83 | 172.11 | 144.78 | Upgrade
|
| Operating Expenses | 17,468 | 22,896 | 19,779 | 29,765 | 26,098 | Upgrade
|
| Operating Income | -242.82 | -3,598 | -3,411 | -8,756 | 2,576 | Upgrade
|
| Interest Expense | -1,984 | -1,654 | -1,952 | -1,580 | -1,205 | Upgrade
|
| Interest & Investment Income | 1,062 | 671.14 | 529.74 | 86.44 | 170.13 | Upgrade
|
| Earnings From Equity Investments | 106.63 | -7.71 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 637.41 | 9.12 | 26.25 | 178.52 | -104.43 | Upgrade
|
| Other Non Operating Income (Expenses) | -1,278 | -3,380 | -1,544 | 8,825 | -9,528 | Upgrade
|
| EBT Excluding Unusual Items | -1,699 | -7,960 | -6,350 | -1,246 | -8,091 | Upgrade
|
| Impairment of Goodwill | - | - | -139.69 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -1,145 | 634.81 | 1,669 | -2,789 | 1,014 | Upgrade
|
| Gain (Loss) on Sale of Assets | -695.3 | -408.8 | -204.32 | -39.9 | -17.83 | Upgrade
|
| Asset Writedown | -70 | -858.01 | -2,370 | 775.97 | -105.56 | Upgrade
|
| Other Unusual Items | 389.14 | - | - | - | 60.82 | Upgrade
|
| Pretax Income | -3,220 | -8,592 | -7,395 | -3,299 | -7,139 | Upgrade
|
| Income Tax Expense | 862.69 | 978.24 | 433.58 | -90.44 | -2,004 | Upgrade
|
| Earnings From Continuing Operations | -4,082 | -9,570 | -7,828 | -3,209 | -5,135 | Upgrade
|
| Earnings From Discontinued Operations | 12,725 | -12,658 | - | -204.51 | -352.81 | Upgrade
|
| Net Income to Company | 8,642 | -22,228 | -7,828 | -3,413 | -5,488 | Upgrade
|
| Minority Interest in Earnings | 1,434 | 1,231 | - | - | - | Upgrade
|
| Net Income | 10,076 | -20,997 | -7,828 | -3,413 | -5,488 | Upgrade
|
| Net Income to Common | 10,076 | -20,997 | -7,828 | -3,413 | -5,488 | Upgrade
|
| Shares Outstanding (Basic) | 43 | 35 | 29 | 21 | 17 | Upgrade
|
| Shares Outstanding (Diluted) | 43 | 35 | 29 | 23 | 17 | Upgrade
|
| Shares Change (YoY) | 22.60% | 21.50% | 27.71% | 32.46% | 11.06% | Upgrade
|
| EPS (Basic) | 231.83 | -592.28 | -268.29 | -159.71 | -318.17 | Upgrade
|
| EPS (Diluted) | 198.77 | -627.05 | -268.29 | -367.60 | -318.46 | Upgrade
|
| Free Cash Flow | -4,652 | -16,130 | -2,780 | -11,648 | -42,966 | Upgrade
|
| Free Cash Flow Per Share | -107.03 | -454.99 | -95.26 | -509.83 | -2491.14 | Upgrade
|
| Gross Margin | 28.33% | 32.54% | 27.74% | 32.51% | 40.42% | Upgrade
|
| Operating Margin | -0.40% | -6.07% | -5.78% | -13.55% | 3.63% | Upgrade
|
| Profit Margin | 16.57% | -35.41% | -13.27% | -5.28% | -7.74% | Upgrade
|
| Free Cash Flow Margin | -7.65% | -27.20% | -4.71% | -18.02% | -60.57% | Upgrade
|
| EBITDA | 2,232 | -739.4 | -1,450 | -6,925 | 4,102 | Upgrade
|
| EBITDA Margin | 3.67% | -1.25% | -2.46% | -10.72% | 5.78% | Upgrade
|
| D&A For EBITDA | 2,475 | 2,859 | 1,961 | 1,830 | 1,526 | Upgrade
|
| EBIT | -242.82 | -3,598 | -3,411 | -8,756 | 2,576 | Upgrade
|
| EBIT Margin | -0.40% | -6.07% | -5.78% | -13.55% | 3.63% | Upgrade
|
| Advertising Expenses | 1,614 | 3,972 | 2,823 | 6,864 | 8,141 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.